Todd Aguilera MD PhD
@aguilera_md
Followers
655
Following
1K
Statuses
456
GI radiation oncologist | END pancreas cancer! | Live and breath science to impact the lives of our loved ones | tweets mine
Joined August 2019
RT @AnthonyjdavisL: I'm excited this study that started before COVID is finally out. Spent a lot of nights in Pavia…
0
4
0
RT @DrewMoghanaki: SBRT helps avoid SYSTEMIC THERAPY INTENSIFICATION in 50% of patients with stage IV cancer without any serious side effec…
0
38
0
RT @jillfeldman4: Yes, very true! SBRT has been both life-changing and life-saving for me. It has helped manage my cancer over the past 9 y…
0
15
0
RT @DavidSherMD: I don't treat HCC, but RFA is clearly inferior to SBRT in this study. The local control (75%) with RFA is poor in absolu…
0
21
0
Way to go! With our IRB now. We hope to open this @utswcancer @UTSW_RadOnc very soon. Congrats Ali!
Exciting news: 1st pnt enrolled #ULTRAS. 1st multicenter MRgRT ph3 RCT for liver met. Single Fx SBRT: BED10 180 vs 100 to improve LC. @aguilera_md @Sunnybrook @teo_stanescu @Hendo_tan @IssaMohamadRad @SweetPingNg @MichaelYanMD @ldawsonmd @DKirschMDPhD @mr_linac @Xristodouleas
0
0
8
RT @santhoshak23220: Radiofrequency Ablation Versus Stereotactic Body Radiotherapy for Recurrent Small Hepatocellular Carcinoma: A Randomiz…
0
9
0
RT @KrishanJethwa: 🔥Brachytherapy boost for high-risk localized rectal cancer🔥 OPERA ph3 RCT demonstrated improved organ preservation w/ b…
0
33
0
RT @NiuSanford: RACE-GB is out! Congrats to authors for FIRST RCT of RT in gallbladder cancer. N=135 w unresectable GBC, after 4c chemo, a…
0
70
0
RT @NiuSanford: @SuyogCancer @5_utr @KrishanJethwa @dr_yakupergun @SABCSSanAntonio Thanks for saying that, helpful when non rad-oncs chime…
0
9
0
RT @NiuSanford: Lastly, on a personal note, I've really enjoyed working with coop groups/@NRGonc. They are arguably the most important mech…
0
4
0
RT @NiuSanford: Huge thanks to my mentor Bill Hall, ALLIANCE statistician Qian Shi & my former research assistant David Hein for collaborat…
0
1
0
RT @NiuSanford: A final point. These basic features on statistical design were often hard to find, and some protocols didn’t include things…
0
1
0
RT @NiuSanford: We also studied alpha, power and effect size, which were broadly similar by modality, although there were outliers. We prov…
0
1
0
RT @NiuSanford: In breast cancer, 75% of radiation studies were omission trials! The raw # of RT trials (even in coop group) is much less t…
0
6
0
RT @NiuSanford: Second, superiority vs. non-inferiority trials. A total of 31% (!) of RT trials were non-inferiority studies assessing radi…
0
8
0
RT @NiuSanford: For trials with non-OS primary endpoint, we categorized the type of endpoint selected. Most were composite surrogate endpo…
0
1
0
RT @NiuSanford: We also stratified by Stage and trial Phase. Even for Stage 4 cancer, 100% of RT trials in prostate/breast/lung/GI had pr…
0
4
0
RT @NiuSanford: First, primary endpoint. Across sites, 59% of radiation trials had primary endpoint of OS versus 27% of systemic trials.…
0
10
0